Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer

Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer

US Patent 11642342 · Granted May 9, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-PD-1 antibodies and uses thereof2025
Apolipoprotein nanodiscs with telodendrimer2025
Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors2025
Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors2025
Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors2025
Smokeless grill2025
Compounds having BET, estrogen receptor, and androgen receptor degradation activ2025
Compounds having BET, estrogen receptor, and androgen receptor degradation activ2025
Compounds and methods for the targeted degradation of androgen receptor2025
Combination cancer immunotherapies with arginine depletion agents2025
Modulators of estrogen receptor proteolysis and associated methods of use2025
Compounds and methods for the enhanced degradation of targeted proteins2025